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1. Introduction 
Vitiligo is an acquired disorder characterized by depigmented macules on skin, hair, and 
mucosa. Its prevalence worldwide is 0.1-2% and varies from country to country.1 It is 
associated with high psychiatric morbidity and dysfunction, particularly in darker skin 
types where the contrast between normal and depigmented skin is highly pronounced.2,3 
The usual approach to the treatment of vitiligo has been to regain pigment in vitiliginous 
areas rather than controlling the disease process. This is akin to treating the effects of the 
disease rather than treating the disease itself. Such an approach frequently results in 
frustration because patients can continue to develop new lesions at other sites even while 
existing lesions are repigmenting, or the disease may be reactivated at a later stage even 
after achieving a fair degree of therapeutic success.4 Therefore, the important priority for the 
treatment of vitiligo should be first to control the disease process, and then taking measures 
to repigment existing lesions. 
Systemic corticosteroids are a broad group of drugs that are widely used in various 
dermatological and non-dermatological conditions. Corticosteroids, both topical and 
systemic, have been used in vitiligo for over four decades with some concern about its 
efficacy as well as its known or expected adverse effects. Further research may provide 
evidence that systemic corticosteroids may be an important modality for the treatment of 
progressive vitiligo.  
2. History 
In 1967, oral corticosteroids were used for the first time in vitiligo. Triamcinolone orally was 
found to have a synergistic effect with methoxypsoralen as compared to methoxypsoralen 
alone.5 In 1976, adrenocorticotropic hormone (ACTH) was found to be effective in inducing 
repigmentation in patients who had previously failed  photochemotherapy with psoralen 
followed by UVA exposure (PUVA).6 In the same year, a mixture of prednisolone, 
betamethasone, paramethasone acetate and methylprednisolone given orally was effective in 
producing satisfactory repigmentation in one-third of patients studied, thus confirming the 
efficacy of corticosteroids in vitiligo.7 Treatment of vitiligo is known to be long-term, hence the 
question of long term safety of systemic corticosteroids is an important consideration. To 
reduce long-term complications of corticosteroids, oral mini-pulse therapy was introduced in 
1989 and was established in 1993, where instead of daily oral corticosteroids, a long-acting 
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corticosteroid was given on two consecutive days of the week.8,9 Since then, systemic 
corticosteroids are used in day-to-day practice in extensive and progressive vitiligo. 
3. Structure and classification  
The structure of corticosteroids consists of three hexane rings and one pentane ring known 
as the cyclopentanoperhydrophenathrene nucleus. The different systemic corticosteroids are 
variations of this basic structure. Systemic corticosteroids are classified according to their 
half-lives. (Table 1) 
 
Corticosteroid 
Equivalent 
dose (mg) 
Glucocorticoid 
potency 
Mineralocorticoid 
potency 
Plasma 
half- life 
(minutes) 
Biological 
half-life 
(hours) 
Short Acting  
Cortisone  25 0.8 2+ 30-90 8-12 
Hydrocortisone  20 1 2+ 60-120 8-12 
Deflazacort 6   90-120 <12 
Intermediate Acting  
Prednisone  5 4 1+ 60 24-36 
Prednisolone 5 4 1+ 115-212 24-36 
Methylprednisolone  4 5 0 180 24-36 
Triamcinolone  4 5 0 78-188 24-36 
Long Acting  
Dexamethasone  0.75 20-30 0 100-300 36-54 
Betamethasone 0.6-0.75 20-30 0 100-300 36-54 
Table 1. Classification of Corticosteroids10,11 
The structure, mechanism of action, and pharmacokinetic profile of various systemic 
corticosteroids are similar. The main difference is in their glucocorticoid and 
mineralocorticoid effects and biological half-life. Hence, the choice of corticosteroid is 
decided by the duration of action needed, the dosing schedule to be used (daily versus 
weekly) and the clinical profile of the patient. Having a working knowledge of equivalent 
dosing helps in dose conversion when one corticosteroid is switched to another. 
4. Mechanism of action of corticosteroids in vitiligo 
Vitiligo is considered to be primarily an autoimmune condition that results in the loss of 
melanocytes. Melanocytes are lost in vitiligo due to the destruction of melanocytes by 
humoral or intrinsic cellular mechanisms.12 Humoral mechanisms involve destruction of 
melanocytes by pathogenic autoantibodies directed against melanocytes and the tyrosinase 
enzyme. Cellular mechanisms are as important as humoral in destroying melanocytes. 
Biopsies from vitiligo lesions show mild mononuclear infiltrate in the margins of lesional 
skin in active vitiligo with or without basal vacuolization. Active lesions show increased 
numbers of CD4+ T cells and increased epidermal expression of ICAM-1.13 Peripheral T-cell 
activation is also seen in nonsegmental vitiligo and T-cell dysregulation is not only limited 
to the lesions.14 The peripheral blood of vitiligo patients express more of the cutaneous 
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lymphocyte-associated antigen positive melanocyte-specific cytotoxic T lymphocytes 
indicating that there is recruitment of T cells in the circulation to the skin.15 Both the CD4+ and 
CD8+ T cells from perilesional and non-lesional skin in vitiligo show polarization towards the 
Type 1 cytokine profile which parallels depigmentation.16 The melanocyte-specific cytotoxic T 
cells found in perilesional biopsies have the ability to infiltrate normal skin and destroy the 
melanocytes.17 Besides cytotoxic T cells, regulatory T cells (T regs) also have a role in vitiligo. 
The T reg population is not decreased in the peripheral circulation, however, these T regs are 
not able to settle in the skin and this defect seems to be crucial in the observed perpetual anti-
melanocyte reactivity in progressive disease.18 
Corticosteroids suppress autoantibody formation and likely induce apoptosis of cytotoxic 
T cells. The autoimmune hypothesis still prevails in the pathogenesis of non-segmental 
vitiligo, and the autoimmune process is not limited to the skin. In progressive disease, 
there is continuous assault on melanocytes. Topical corticosteroids, tacrolimus or any 
other topical agent may suppress autoimmune dysfunction at the site of a vitiligo lesion, 
but these do not have any effect on the disease process per se. Photochemotherapy and 
phototherapy stimulate melanocytes to cause repigmentation and have minimal 
immunomodulatory action on T-lymphocytes, but may not halt the rapid destruction of 
melanocytes. Systemic corticosteroids act not only on lesional immune activity, but also 
on the T cells in peripheral circulation. Besides modulating cell-mediated immunity, 
corticosteroids also suppress autoantibody formation. The serum of actively spreading 
vitiligo patients who received oral corticosteroids and showed improvement had a 
decrease in complement-mediated cytotoxicity by melanocyte autoantibodies and a 
reduced antibody titer to the melanocyte surface antigen.19 
5. Indications 
Systemic corticosteroids are the first-line treatment when a patient presents with rapidly 
progressive vitiligo. It helps not only in halting progression of the disease, but also induces 
repigmentation as normal melanocytes from the periphery of the lesions or perifollicular 
area take over, once the process of melanocyte destruction is arrested. Assessment of 
treatment response is important and since the patient is not always sure whether new 
lesions have appeared or not since corticosteroid initiation, a baseline photographic record 
must be taken before starting treatment and periodically throughout treatment, preferably 
at 4-week intervals. The time taken for disease activity to stop is variable and may range 
from a few weeks to months. Once stability is achieved (defined as no new lesion formation 
and no extension of existing lesions), one must taper the corticosteroids slowly and add 
other modalities for augmentation of repigmentation.  
Patients with extensive slowly progressive vitiligo (body surface area more than 10% with 
the continuous appearance of new lesions or slow extension of existing lesions) may also 
benefit from systemic corticosteroids as this suggests “simmering” autoimmune activity that 
may be long-term. Besides maintenance therapy, episodic treatment for 8-12 weeks at a time 
can also be added whenever there is relapse.  
For example, systemic corticosteroids can also be added to photochemotherapy or 
phototherapy when there is transient fluctuation or worsening of disease activity. It can also 
be an adjuvant to surgery in both segmental and nonsegmental vitiligo.20,21 
It is not advisable to use corticosteroid monotherapy in segmental vitiligo because 
segmental vitiligo is known to stabilize after some time. The initial period of progression 
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may be rapid in segmental vitiligo, but nearly all lesions stabilize and remain confined to 
one part of the body. Hence use of corticosteroids may not be advisable. Patients with stable 
vitiligo will also not benefit from corticosteroids because they are not simply repigmentation 
agents; rather their efficacy comes from their effects on active disease. Universal or near-
universal vitiligo is also not an indication for the use of corticosteroids since treatment is 
usually depigmentation of residual pigmented areas. 
6. Modes of administration 
Systemic corticosteroids given orally are effective in halting progression of vitiligo and 
producing repigmentation. However, the long treatment duration required in vitiligo raises 
concern about the long-term cumulative side effects of corticosteroids. Daily doses or 
alternate day dosing is thereby avoided in vitiligo. Therefore, oral mini pulse therapy (OMP) 
is preferred for the planned long-term maintenance therapy for 6 months or beyond.9 OMP 
refers to giving a higher than the usual daily dose of corticosteroid on two consecutive days 
a week and leaving the remaining five days treatment-free. A long-acting corticosteroid is 
preferred so that the effect lasts for about 3 days at a time.  Corticotropin and cortisol levels 
fall rapidly after the second dose of drug, but returns to baseline before the next 
dexamethasone pulse.22 Hence, it is preferred to give a long-acting corticosteroid on two 
consecutive days in a week rather than once in three days to give the hypothalamic-
pituitary-adrenal axis (HPA) axis time to revert back to normal before the next dose. The 
standard regimen is to give oral betamethasone 5 mg (5 of the 1 mg betamethasone tablets) 
after breakfast on Saturday and Sunday (or any other two consecutive days) every week.9 
Dexamethasone pulse has been used in doses of 5 mg or 10 mg in this manner.22,23 
Betamethasone pulse has been given as an adjunct with surgery.24 Besides this standard 
regimen, there can be variations in OMP. If no response is seen, the dose can be increased 
from 5 mg upto 7.5 mg. In children, dose is reduced from 5 mg to 2.5-4 mg. Additional 
immunosuppressants, for example, cyclophosphamide and azathioprine, may also be added 
to the therapeutic regimen. 
Methylprednisolone25 has been used intravenously as high dose pulse therapy given on 3 
consecutive days in a month but should not be considered as first-line treatment. Daily low 
dose prednisolone has also been used in tapering doses to discontinuation.26,27  
The intramuscular route is not preferred as it is painful, and the level of drug in the 
circulation is unpredictable and good results are achieved by oral administration. 
Monitoring of weight, fasting blood sugar, and blood pressure every month is necessary for 
any patient on systemic corticosteroids. Baseline and periodic photographs should also be 
done to monitor treatment response and repigmentation. 
7. Side effects and contraindications 
Systemic corticosteroids are known to have a variety of adverse effects. The predominant 
side effects are described in Table 2. However, these adverse effects do depend on dose, 
duration of treatment, and individual susceptibility. All patients do not develop the same 
adverse effects. Therefore, clinical evaluation and monitoring is the best way to ascertain 
whether adverse effects are minimal or serious, and reversible or irreversible. Minimal and 
reversible side effects are acceptable for continuing treatment. 
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System Affected Side Effects 
HPA Axis  Steroid withdrawal syndrome, Addisonian crisis  
Metabolic  
Hyperglycemia, increased appetite and weight gain, 
hypertension, congestive heart failure, hypokalemia, 
hypertriglyceridemia, cushingoid changes, menstrual 
irregularities 
Bone  Osteoporosis, osteonecrosis, hypocalcemia 
Gastrointestinal  
Peptic ulcer disease, bowel perforation, fatty liver changes, 
esophageal reflux, nausea, vomiting 
Ocular  Cataracts, glaucoma, infections 
Psychiatric  Psychosis, agitation, depression  
Neurological  Pseudotumor cerebri, peripheral neuropathy 
Muscular  Myopathy  
Cutaneous  
Delayed wound healing, acneiform eruption, purpura, 
cutaneous infections, telogen effluvium, hirsutism, acanthosis 
nigricans 
Table 2. Side Effects of corticosteroids10 
The primary consideration in treating vitiligo is careful patient selection in order to 
maximize response to vitiligo while minimizing adverse effects. The other concern is 
determination of proper dose and dosing schedule. 
Side effects can be dose- or duration-dependent. Dose-dependent side effects of 
corticosteroids are hyperglycemia, hyperlipidemia, peptic ulcer disease, and psychosis. 
Duration-dependent changes are hypertension, cushingoid changes, growth impairment, 
osteoporosis, osteonecrosis and opportunistic infections.10 Steroid withdrawal syndrome is 
observed when systemic corticosteroids given at high doses are abruptly stopped and it 
presents as vague symptoms of lethargy, generalized weakness and myalgia. Abrupt 
withdrawal of the corticosteroid does not give enough time for the suppressed HPA axis to 
recover. It is observed with doses higher than 20-30 mg of prednisolone. Duration of 
treatment is not a predictable causative factor.28 High dose of corticosteroid can also lead to 
extreme suppression of adrenals (Addisonian crisis) manifesting as hypotension and 
extreme weakness. Cushingoid changes occur with long term treatment and present as 
puffiness of face, moon facies, buffalo hump, striae, increased hair growth on face, skin 
atrophy, increased abdominal girth with thin extremities and others. Growth impairment 
and opportunistic infections can be decreased by avoiding daily administration either by 
using alternate day dosing or OMP. Oral mini pulse therapy has fewer side effects (e.g., 
moon facies, weight gain, acne) compared to daily dosing as reviewed in a meta-analysis.29 
Betamethasone and dexamethasone can be used interchangeably as the potency and half-life 
are almost same. When compared to other corticosteroids, deflazacort is considered to have 
relatively fewer cases of growth retardation in children, osteoporosis, weight gain and HPA 
axis suppression.11  
Absolute contraindications to use of systemic corticosteroids are very few, and include such 
conditions as systemic fungal infections and herpes simplex keratitis. Relative 
contraindications are congestive heart failure, human immunodeficiency virus (HIV), 
psychosis, active peptic ulcer disease, active tuberculosis, and septicemia. Well-controlled 
diabetes and hypertension are not  contraindications, but lower doses should be used, the 
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concomitant disease must be adequately treated, and the patient should be monitored 
frequently. 
There are various approaches to minimize the side effects of corticosteroids. First is to give 
corticosteroids only as long as disease activity is present and the taper it slowly (over a 
period of 3-6 months) when no indication of new lesions are present. The oral mini pulse 
therapy regimen has significantly less side effects compared to typical daily dosing of 
corticosteroids. An important finding is the lack of prolonged HPA axis suppression with  
OMP therapy.22 Furthermore, higher doses of dexamethasone (10 mg) do not seem to 
provide any additional benefit to 5 mg betamethasone.9, 22 Choosing corticosteroids with less 
risk of mineralocorticoid-type effects (i.e., dexamethasone, betamethasone) or one with 
supposedly fewer side effects (i.e., deflazacort) can be beneficial for all patients. Calcium 
supplementation, salt restriction, proper diet, daily exercise and use of antacids can 
minimize risk of side effects. Regular monitoring of weight, fasting blood sugar, and blood 
pressure will help in early detection of side effects if they  occur. 
8. Safety in children and pregnancy 
The decision to treat progressive vitiligo in children below 4 years of age can be rather 
difficult as limited data is available for this population. It is suggested that oral mini pulse 
therapy be modified (i.e., 1 mg of dexamethasone or betamethasone given for every 10 kg) 
and used. 
Corticosteroids have been safely used in pregnancy and are classified as category C drugs 
(animal reproduction studies have shown an adverse effect on the fetus and there are no 
adequate and well-controlled studies in humans, but potential benefits may warrant use of 
the drug in pregnant women despite potential risks). However, it is best to reserve its use in 
pregnancy when the benefits of treatment outweigh the risk of side effects. Pregnancy is 
known to precipitate and aggravate vitiligo. However, vitiligo being a non-life threatening 
condition, a patient may defer any type of treatment, including corticosteroids. 
9. Efficacy of corticosteroids in vitiligo  
Worldwide, there are few studies published documenting the efficacy and safety of 
corticosteroids in vitiligo. The available reports are primarily case series and there is a lack 
of well validated randomized controlled trials. 
9.1 Oral mini pulse therapy 
Pasricha et al evaluated the effect of five different regimens in causing repigmentation and 
stopping disease activity for four months and noted that regimens using corticosteroids 
were superior to those excluding corticosteroids. Improvement with 3 mg betamethasone 
orally on alternate days combined with levamisole and topical fluocinolone, 2 mg 
betamethasone orally alternating with 20 mg 8-methoxypsoralen and sun exposure, and oral 
mini pulse consisting of 5 mg betamethasone orally twice a week combined with 50 mg 
cyclophosphamide daily orally was 87.5%, 85% and 90.9% respectively, while levamisole 
150 mg two days a week showed improvement in 53.8%. Addition of topical fluocinolone 
acetonide to levamisole showed better response in 81.8%.8 
In a study on forty patients by Pasricha and Khaitan, 5 mg betamethasone as a single oral 
dose after breakfast on 2 consecutive days per week was found effective in halting disease 
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progression in 89% patients within 1-3 months and inducing variable spontaneous 
repigmentation in patients with extensive and rapidly progressive disease.9 Only 2 patients 
did not show response initially, but once the dose was increased from 5 mg to 7.5 mg, there 
was notable improvement. Side effects were seen in 23%(17) patients, such as weight gain 
(5), mild headache (2), transient general weakness (2), bad taste in mouth (3), acne (2) and 
mild puffiness, perioral dermatitis, as well as herpes zoster, glaucoma and amenorrhea, of 
which were reported in one patient each. Kanwar et al23and Radakovic-Fijan et al22 also 
reported efficacy of dexamethasone oral mini pulse therapy in arresting progression of 
rapidly spreading vitiligo in 43.8% and 88%, respectively. The difference in response in this 
study by Kanwar et al and the one conducted by Pasricha and Khaitan could be because of 
the higher proportion of patients with segmental vitiligo and shorter duration of treatment 
in the Kanwar et al study.  
OMP has been found to be effective in patients with unstable generalized and acrofacial 
vitiligo in a randomized double-blind placebo-controlled randomized prospective study.30  
Prednisolone has been used as once a week oral dose of 2 mg/kg in 50 patients with 
extensive and rapidly spreading vitiligo. The disease progression was arrested in 93% and 
repigmentation observed in 88% with only 3 patients developing side effects.31 
Methylprednisolone 0.8mg/kg given as OMP along with topical fluticasone in children for 6 
months was safe and effective in arresting disease in 90% and producing variable 
repigmentation in 65%.32  
OMP in combination with other standard vitiligo treatments has also been studied. 
Betamethasone has been used as an adjunct to surgery for treatment of stable vitiligo 
patches in patients who did not respond to their first surgical.24 It has also been combined 
with phototherapy and photochemotherapy. Dexamethasone OMP has been found effective 
and safe with psoralen with solar ultraviolet light (PUVAsol) in fast spreading vitiligo.30 
OMP has been safely used in children and was more effective than 8-methoxypsoralen 
alone.33 Combination of narrowband UVB (NB-UVB) with OMP has been compared with 
psoralen and ultraviolet A (PUVA) photochemotherapy with OMP. Disease progression is 
arrested in both, but repigmentation was better and earlier with NB-UVB.34 
Immunosuppressants can also be added to OMP. A comparison study of three regimens: (a) 
OMP with daily cyclophosphamide, (b) a 3-day dexamethasone-cyclophosphamide pulse 
given monthly, and (c) daily cyclophosphamide and  dexamethasone-cyclophosphamide 
pulse given only on one day in a month showed that disease activity was arrested by all 
three modalities but repigmentation up to 75% was seen in 71%, 62%, and 53%, respectively. 
The higher response with OMP may be because weekly dosing may provide better 
immunosuppression in the context of vitiligo as compared to monthly dosing in pulse 
therapy.35 Weight gain was more frequent with OMP, but otherwise all three regimens had a 
similar frequency of side effects.35 
9.2 Daily corticosteroids 
In everyday practice, corticosteroids are primarily administered daily at doses individualized 
for each specific patient. Published studies are based on prednisolone given at 0.3mg/kg  as a 
single oral dose after breakfast initially for the first 2 months. The dosage is then reduced to 
half the initial dose during at the third month and halved again in at the fourth month of 
treatment. With this regimen, Kim et al noted that disease progression was halted in 87.7% of 
patients and in 70.4%, repigmentation was also seen.26 In a study by Banerjee et al, disease 
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progression was arrested in 90% and repigmentation was seen in 76%.27 The side effects 
observed in both studies were not serious, and did not warrant a change in dose or dosing 
schedule. Disease was also reported to completely subside after discontinuing treatment in 
addition to other positive observations; this suggests that  low dose corticosteroids given for 4 
months may be reasonably safe and effective treatment option.  
9.3 Intravenous pulse therapy 
Methylprednisolone (8 mg/kg) given intravenously on three consecutive days a month was 
used in a study as pulse therapy in 14 patients with generalized vitiligo. Eighty-five percent of 
the patients who presented with progressive disease showed cessation of disease progression 
and 71% of these patients had repigmentation. None of the six patients presenting with static 
disease showed any repigmentation. The therapy was well tolerated in all but one patient who 
developed intermittent arterial hypertension during therapy.36 
Most studies indicate that systemic corticosteroids are helpful in halting disease progression 
in rapidly spreading vitiligo and inducing spontaneous repigmentation. However their role 
in static vitiligo is not well documented. As of now, corticosteroids can be recommended for 
rapidly spreading vitiligo for a short duration to halt disease activity, but it should not be 
used for  repigmentation in static vitiligo, even if disease is extensive. Areas that require 
further research is the risk of osteoporosis with corticosteroids and the efficacy of  calcium 
supplementation. Studies with longer follow-up periods are required to evaluate the 
potential for relapse. Deflazacort needs to be evaluated as a relatively safer corticosteroid 
option for vitiligo since its use in vitiligo is very limited. Head-to-head comparative studies 
between betamethasone, prednisolone, and deflazacort may be useful for determining the 
optimal agent for treatment.  
10. Conclusion  
There seems to be a definite role for systemic corticosteroids in the treatment of vitiligo. The 
types of vitiligo in which benefits have been observed are: (a) rapidly progressing vitiligo, 
(b) slowly progressing vitiligo with extensive involvement and frequent exacerbation, (c) 
frank inflammatory vitiligo, (d) patients with direct or indirect evidence of autoimmune 
disease (e.g., high titers of thyroid autoantibodies), (d) recalcitrant static vitiligo with 
exacerbation, and (e) rescue therapy. Corticosteroids should not usually be considered for 
universal vitiligo, segmental vitiligo or focal limited vitiligo. 
Although daily or alternate day oral corticosteroids may be treatment options, OMP therapy 
seems to be the best regimen for long-term use with minimal side effects. The duration of 
OMP should be at least 6 months or longer and tapering to discontinuation should be slow 
and step-wise. When a patient is on any regimen that includes systemic corticosteroids, 
regular and periodic monitoring must be done to assess the risk-to-benefit ratio of treatment 
and to evaluate efficacy. Further study is needed to provide more definitive evidence for 
systemic corticosteroid use in vitiligo as well as the long-term implications of treatment. 
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